Man Group plc acquired a new stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 153,557 shares of the biopharmaceutical company’s stock, valued at approximately $940,000. Man Group plc owned approximately 0.25% of Vanda Pharmaceuticals at the end of the most recent quarter.
Several other institutional investors and hedge funds have also bought and sold shares of the company. Hsbc Holdings PLC bought a new position in Vanda Pharmaceuticals in the 2nd quarter valued at $579,000. Canada Pension Plan Investment Board bought a new position in shares of Vanda Pharmaceuticals in the second quarter worth $123,000. Legal & General Group Plc purchased a new stake in shares of Vanda Pharmaceuticals in the second quarter worth $34,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Vanda Pharmaceuticals in the second quarter worth $93,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in Vanda Pharmaceuticals during the second quarter valued at $1,317,000. 88.14% of the stock is currently owned by hedge funds and other institutional investors.
Vanda Pharmaceuticals Trading Down 3.4%
Shares of VNDA stock opened at $5.34 on Friday. The business has a 50-day moving average price of $5.52 and a two-hundred day moving average price of $6.45. Vanda Pharmaceuticals Inc. has a 12-month low of $4.27 and a 12-month high of $9.94. The company has a quick ratio of 1.60, a current ratio of 1.61 and a debt-to-equity ratio of 0.01. The firm has a market cap of $322.86 million, a P/E ratio of -1.15 and a beta of 0.64.
Wall Street Analysts Forecast Growth
VNDA has been the subject of several recent analyst reports. B. Riley Financial restated a “buy” rating and set a $12.00 target price (down from $17.00) on shares of Vanda Pharmaceuticals in a research report on Monday, August 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Friday, July 17th. Wall Street Zen lowered Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, HC Wainwright lowered their target price on shares of Vanda Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Vanda Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $13.70.
View Our Latest Stock Analysis on Vanda Pharmaceuticals
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.
Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.
Read More
- Five stocks we like better than Vanda Pharmaceuticals
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
